Smith & Nephew plc vs Vanguard Emerging Markets Stock Index Fund ETF — how do they compare? Smith & Nephew plc trades at $27.24 (market cap $11.10B), while Vanguard Emerging Markets Stock Index Fund ETF trades at $59.76 (market cap $168.50B). The key difference: Vanguard Emerging Markets Stock Index Fund ETF is far larger — about 15.2× Smith & Nephew plc's market cap, and Smith & Nephew plc pays a 2.95% dividend while Vanguard Emerging Markets Stock Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Smith & Nephew plc for 121 Days and Vanguard Emerging Markets Stock Index Fund ETF for 135 Days on average.
| SNN | VWO | |
|---|---|---|
Market Cap | $11.10B | $168.50B |
Volume | 1,051,703 | 9,650,999 |
Sector | Health | — |
52-Week High | $37.17 | $61.44 |
52-Week Low | $26.42 | $52.42 |
Typical Hold Time | 121 Days | 135 Days |
Enterprise Value | $14.13B | — |
Dividend Yield | 2.95% | — |
Signals from Pluang's Aura AI — not financial advice
Smith+Nephew (SNN) trades at $27.24, near its 52-week low of $27.05, with a bearish technical signal despite recent earnings beats. Revenue grew to $6.16B in 2025, with net income margin improving to 10.08%, but the stock faces headwinds from analyst downgrades and CFO departure news. Product launches like the EVOS PELVIC System highlight innovation, yet investor sentiment remains cautious.
The outlook is mixed: strong fundamentals and undervaluation (P/E 18.34) offer upside, but technical weakness and competitive risks temper near-term gains. Key risks include execution challenges and market volatility, while institutional interest (e.g., BlackRock's $505M stake) provides support. Investors should weigh solid profitability against sentiment-driven price pressure.
VWO trades at $59.76, down 0.15% on the day, with technical indicators showing a bearish bias as moving averages signal selling pressure. The ETF's emerging markets focus faces headwinds from China's economic slowdown, though AI-driven semiconductor demand in Taiwan provides some offset. Recent institutional buying by firms like Allianz and Alamar Capital suggests confidence in long-term emerging markets exposure despite near-term challenges.
The outlook remains cautious given China's persistent weakness and technical bearish signals, though institutional accumulation and AI infrastructure spending offer potential catalysts. Key risks include concentrated emerging markets exposure and currency volatility, requiring careful position sizing for investors seeking diversification beyond developed markets.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →The fund employs an indexing investment approach designed to track the performance of the FTSE Emerging Markets All Cap China A Inclusion Index. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the index in terms of key characteristics.
Read more on VWO →